{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:03:40Z","timestamp":1781921020398,"version":"3.54.5"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T00:00:00Z","timestamp":1422403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0114828","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T18:57:33Z","timestamp":1422471453000},"page":"e0114828","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Evolution of BCR\/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor"],"prefix":"10.1371","volume":"10","author":[{"given":"Shantashri","family":"Vaidya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu Rao","family":"Vundinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrakala","family":"Shanmukhaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prantar","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanjaksha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,1,28]]},"reference":[{"issue":"23","key":"ref1","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1002\/cncr.24601","article-title":"Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"issue":"17","key":"ref2","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","article-title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib","volume":"116","author":"DW Sherbenou","year":"2010","journal-title":"Blood"},{"issue":"35","key":"ref3","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet","volume":"27","author":"M Baccarani","year":"2009","journal-title":"Journal of clinical oncology"},{"key":"ref4","first-page":"6","article-title":"ISCN: an international system for human cytogentic nomenclature","author":"LG Shaffer","year":"2009"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"S Branford","year":"2003","journal-title":"Blood"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"M Azam","year":"2003","journal-title":"Cell"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"C Lestienne","year":"2002","journal-title":"Blood"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/hon.894","article-title":"Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent","volume":"27","author":"SH Kim","year":"2009","journal-title":"Hematol Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of abl kinase domain mutations to imatinib in different subsets of Philadelphia-positive patients: by GIMEMA working party on chronic myeloid leukemia","volume":"12","author":"S Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref10","first-page":"3075","article-title":"Mutator phenotype may be required for multistage carcinogenesis","volume":"51","author":"LA Loeb","year":"1991","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/289353a0","article-title":"The origin of human cancers","volume":"289","author":"J Cairns","year":"1981","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-010-1039-5","article-title":"Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients","volume":"90","author":"Y Qin","year":"2011","journal-title":"Ann Hematol"},{"key":"ref13","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"L Wang","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"N Shah","year":"2002","journal-title":"Cancer cell"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"19585","DOI":"10.1074\/jbc.271.32.19585","article-title":"An activating mutation in the ATP binding site of the ABL kinase domain","volume":"271","author":"PB Allen","year":"1996","journal-title":"J. Biol. Chem"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/j.leukres.2012.02.005","article-title":"Imatinib resistance due to a novel tri-nucleotide insertion in the SH2\/C lobe interface of BCR\/ABL kinase domain between position K357 and N358","volume":"36","author":"S Vaidya","year":"2012","journal-title":"Leukemia Research"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/leu.2008.65","article-title":"Characterization of BCR\/ABL deletion mutants from patients with chronic myeloid leukemia","volume":"22","author":"DW Sherbenou","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"E Jabbour","year":"2008","journal-title":"Blood"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF03262214","article-title":"Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations","volume":"16","author":"F Razga","year":"2012","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"P Rousselot","year":"2007","journal-title":"Blood"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0609.2004.00257.x","article-title":"Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia","volume":"72","author":"W Ghanima","year":"2004","journal-title":"Eur J Haematol"},{"issue":"7","key":"ref22","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"S Merante","year":"2005","journal-title":"Haematologica"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0114828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T02:18:58Z","timestamp":1540347538000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0114828"}},"subtitle":[],"editor":[{"given":"Laszlo","family":"Buday","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,1,28]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0114828","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,28]]}}}